India, Aug. 4 -- Moderna Inc. (MRNA) has dosed the first participants in a Phase 1 clinical trial of its investigational vaccine mRNA- 1469, designed to prevent infection caused by Bundibugyo ebolavirus- a strain of Ebola for which no licensed vaccine currently exists.
The study, authorized by Health Canada, is being conducted at three sites across the country and will evaluate the safety, tolerability and immune response of the vaccine in approximately 80 healthy adults.
Developed using Moderna's mRNA platform, the same technology that enabled rapid global deployment of COVID-19 vaccines, mRNA-1469 builds on the company's ongoing research in filoviruses, which include Ebola-related pathogens.
CEO Stephane Bancel said the initiation mark...